Giacomo Lanzoni, PhD

Assistant Professor, Diabetes Research Institute, Department of Biochemistry and Molecular Biology, University of Miami

Dr. Lanzoni`s research is focused on regenerative medicine for Type 1 Diabetes and diabetes complications. He is developing cell-based therapies to modulate immunity, block inflammation, and regenerate tissues. To modulate immunity, he is utilizing Mesenchymal Stem Cells (MSCs) and their derivatives. With his translational and clinical research, he showed that human MSCs robustly inhibit inflammatory responses and determine substantial clinical improvements. He made pioneering observations in a Phase 1/2a clinical trial of MSC treatment in patients with severe COVID-19. He has observed that MSC and their derivatives modulate immune responses, blocking master regulators of inflammation and stimulating regulatory functions. He is now developing MSC-based treatments for Type 1 Diabetes and Chronic Kidney Disease. To regenerate tissues, he harnesses stem and progenitor cells. In this field, he has contributed to the identification of adult progenitor cells in the human biliary tree and pancreas. He is developing novel methods for the transplantation of stem cell derivatives with localized immunomodulation. Dr. Lanzoni has 17 years of experience in the field of regenerative medicine and translational research. He has recently co-founded AION Healthspan, a company developing regenerative medicine strategies to support a healthy lifespan. He is Assistant Professor in Biochemistry and Molecular Biology at the Diabetes Research Institute of the University of Miami, the largest U.S. research institution focused on Type 1 Diabetes. He leads a team focused on translating research findings from the bench into clinical trials.